Naringin ameliorates cognitive deficits in streptozotocin-induced diabetic rats

Xianchu Liu 1, Ming Liu 1, Yanzhi Mo 1, Huan Peng 1, Jingbo Gong 1, Zhuang Li 1, Jiaxue Chen 1, Jingtao Xie 1*

1Department of Applied Psychology, Hunan University of Chinese Medicine, Hunan, PR China

Abstract

Objective(s): Previous research demonstrated that diabetes is one of the leading causes of learning and memory deficits. Naringin, a bioflavonoid isolated from grapefruits and oranges, has potent protective effects on streptozotocin (STZ)-induced diabetic rats. Recently, the effects of naringin on learning and memory performances were monitored in many animal models of cognitive impairment. However, to date, no studies have investigated the ameliorative effects of naringin on diabetes-associated cognitive decline (DACD). In this study, we investigated the effects of naringin, using a STZ-injected rat model and explored its potential mechanism.

Methods: Diabetic rats were treated with naringin (100 mg/kg/d) for 7 days. The learning and memory function were assessed by Morris water maze test. The oxidative stress indicators [superoxide dismutase (SOD) and malondialdehyde (MDA)] and inflammatory cytokines (TNF-α, IL-1β, and IL-6) were measured in hippocampus using corresponding commercial kits. The mRNA and protein levels of PPARγ were evaluated by real time (RT)-PCR and Western blot analysis.

Results: The results showed that supplementation of naringin improved learning and memory performances compared with the STZ group. Moreover, naringin supplement dramatically increased SOD levels, reduced MDA levels, and alleviated TNF-α, IL-1β, and IL-6 compared with the STZ group in the hippocampus. The pretreatment with naringin also significantly increased PPARγ expression.

Conclusion: Our results showed that naringin may be a promising therapeutic agent for improving cognitive decline in DACD.

Introduction

Diabetes mellitus results from defects in insulin secretion and/or insulin function and causes glucose metabolic disorders with some secondary complications affecting eyes, kidneys, heart, and brain (1). Patients and animals’ brains with diabetes mellitus show widespread angiopathy and degenerative abnormalities. It was previously reported that diabetes mellitus have adverse effects on nervous systems, resulting in cognitive impairment (2). In 2006, a new concept “diabetes-associated cognitive decline (DACD)” has been proposed on the importance of strengthening the learning and memory deficits in both clinical and experimental settings (3).

The pathogenesis of cognitive dysfunction seems to be triggered by many factors in diabetic patients (4). Hyperglycemia leads to oxidative stress and inflammatory response, which are the risk factors of Alzheimer’s disease (AD) in diabetes mellitus (5-7). The oxidative stress increased in diabetes mellitus, causes morphological and functional alterations in the hippocampus, due to the excessive production of malonaldehyde (MDA) and decreased efficiency of superoxide dismutase (SOD). Inflammation related to DACD, manifested as dysregulated production of TNF-α, IL-1β, and IL-6 plays a crucial role in insulin resistance (8-9). Peroxisome proliferator-activated receptor (PPAR γ), a ligand-dependent transcription factor, is involved in type 2 insulin-resistant diabetes. Activation of the PPARγ, with anti-inflammatory and antioxidant effects, can increase insulin sensitization and modulate insulin-mediated glucose (10-12).

Naringin, a naturally flavanone glycoside in grapefruits and oranges, has been widely used in traditional medicine. It has been reported to possess antiapoptotic, antiosteoporosis, antiulcer, antioxidant, antiinflammatory, and anticarcinogenic properties (13-14). Emerging data indicate that naringin is involved in amelioration of hyperglycemia. Naringin possesses lipid-lowering and insulin-like properties to decrease insulin resistance,
Table 1. Primer sequences used in RT-PCR for GAPDH and PPARγ

| Gene  | Primer sequences                      | Produce size | TM(°C) | Cycles |
|-------|---------------------------------------|--------------|--------|--------|
| GAPDH | Forward : 5’ AAGTTCAACGGCAAGTCAA 3’  | 466 bp       | 58     | 32     |
|       | Reverse : 5’ ATGCAGGATTGTGGTTG 3’     |              |        |        |
| PPARγ | Forward : 5’ CCAAGTGCTCAGAAGTAG 3’   | 411 bp       | 60     | 32     |
|       | Reverse : 5’ AGATCAGACTCTCGGGCTT 3’  |              |        |        |

hypeglycemia, and dyslipidaemia. Recent findings in epidemiological and dietary interventional studies suggest the possible role of naringin in the treatment of learning and memory (15). Naringin administration prevents and delays neurodegeneration in aluminum chloride-induced cognitive deficits (16). Moreover, naringin reverses a glucose uptake defect and improves cognitive function in the APPsw/PSΔE9 transgenic mouse model of Alzheimer’s disease (17). More importantly, neuroprotective effect of naringin is a result of its antioxidant and anti-inflammatory activity to protect against kainic acid-induced status epilepticus in rats (18). However, there is little information on the effect of naringin on DACD. Hence, the purpose of this study was to assess the effect of naringin treatment on cognitive, in streptozotocin (STZ)-induced diabetic rats.

Materials and Methods

Animals
Male Wistar rats (210–230 g) were purchased from Hunan SJA Laboratory Animal Co, Ltd (Changsha, China). They were kept under specific pathogen free (SPF) environment with free access to water and rodent chow. The experiments were executed in accordance with the Experimental Animal Care and Use Committee of Hunan University of Chinese Medicine (Changsha, China).

Chemicals and drugs
STZ and naringin were purchased from Sigma Chemicals. Level of specific markers for oxidative stress including MDA and SOD in hippocampus tissues was analyzed by commercial kits (Cat. No: A003-1 for MDA, A001-1 for SOD, Nanjing Jiancheng Bioengineering Institute, China). The activities of TNF-α, IL-1β, and IL-6 were evaluated by the commercial immunoassay kits (Cat. No: RTA00 for TNF-α, SRLB00 for IL-1β, and R6000B for IL-6, R&D Systems, USA).

Induction and assessment of diabetes
Diabetic model was induced by IP injection of a single dose of 65 mg/kg STZ. Seven days after STZ injection, fasting blood glucose level was determined. The control animals were injected with citrate buffer. Animals were considered diabetic if plasma glucose level exceeded 7.8 mmol/L (19). Animals in each experiment were randomly assigned to four groups: (1) Control group (Con) (n= 20); normal rats treated with saline, IP (physiological saline 0.1 ml/100 g), (2) Vehicle group (DM) (n=20); diabetic rats treated with saline, IP (physiological saline 0.1 ml/100 g), (3) DM+Naringin group (n=20); diabetic rats treated with naringin (100 mg/kg/d), for 7 days.

Morris water maze test
After naringin treatment for 7 days, the Morris water maze test was conducted to assess the learning and memory performance. The escape latency and path length were evaluated in each trial and averaged over three trials for each rat. The frequency the rat reached the platform, as well as the time spent in the target quadrant were detected within 60 sec (20).

RNA extraction and real time-PCR analysis
The total RNA was extracted from hippocampus samples using the trizol method, as directed by the manufacturer’s protocol. Real time (RT)-PCR was used to determine the levels of PPARγ expressions. Primer sequences were synthesized by Shanghai Sangon Biotech Engineering Co, Ltd. (Shanghai, China) and summarized in Table 1. The RT-PCR consisted of 32 cycles (at 95 °C for 30 sec, 58/60 °C for 40 sec, and 72 °C for 8 min) after an initial denaturing step (at 95°C for 5 min). The software used for bands analysis was designed by Shanghai Tanon Technology Co, Ltd. (Shanghai, China). The results were represented as a ratio by normalizing to GAPDH mRNA levels.

Western blot analysis
The soluble proteins were separated on a 12% acrylamide gel and transferred onto a nitrocellulose membrane. Samples were incubated with primary antibody specific for PPARγ (Proteintech, 16643-1-AP, 1:1000, at 4 °C, overnight). Primary antibodies were visualized with anti-rabbit HRP-conjugated secondary antibody using a chemiluminescent detection system (CowIn Biotech, Beijing, China). Variations in sample loading were corrected by normalizing to β-actin levels.

Statistics
All results were represented as mean±SD. All statistical analyses were analyzed by SPSS 16.0 software. The data of trials in MWM were analyzed by repeated measurement ANOVA, while the others were evaluated using one-way ANOVA. P < 0.05 was deemed statistically significant.
Results

Effects of naringin on diabetes-induced cognitive deficit
After 7 days of naringin treatment, the Morris water maze task was used to assess the cognitive performance in different groups. Diabetic rats exhibited longer escape latency (P<0.01) than the control group, while naringin remarkably decreased the mean escapes latency (P<0.01), as illustrated in Figure 1A. Likewise, there was obvious reduction of number of times the diabetic rats crossed the former platform location (P<0.01), in comparison with control group. However, administration with naringin statistically increased number of times during the probe trial, compared with the STZ-treated group (P<0.01).

Effects of naringin on diabetes-induced changes in oxidative stress
As shown in Figure 2A, the oxidative production of MDA was markedly increased in STZ-induced diabetic rats (P<0.01). Nevertheless, treatment with naringin statistically inhibited the content of MDA (P<0.01). In contrast, Figure 2B shows that antioxidant enzymes production including SOD was significantly reduced in the hippocampus of the STZ-treated rats. Administration of naringin significantly increased the SOD activity in the hippocampus, compared with the STZ-treated group (P<0.01).

Effects of naringin on inflammatory cytokines in the hippocampus of STZ-treated rats
To investigate the effect of naringin on the inflammation induced by diabetes in the hippocampus, major inflammatory factors including TNF-α, IL-1β, and IL-6 were detected by the commercial immunoassay kits. The levels of TNF-α, IL-1β, and IL-6 were all significantly augmented in the hippocampus of STZ-injected rats (P<0.01), compared with those of the control group; while, naringin treatment differentially regulated STZ-induced TNF-α, IL-1β, and IL-6 levels (P<0.01), as displayed in Figure 3. Together, these data indicate that the protective effects of naringin on STZ-induced inflammation could at least partially be the consequence of TNF-α, IL-1β, and IL-6 release in the hippocampus.
Diabetes mellitus is associated with abnormal regulation of glucose and impaired carbohydrate utilization. Hyperglycemia associated biochemical changes lead to hypoglycaemic brain injury which is involved in the occurrence of oxidative stresses and inflammation. Oxidative stress causes morphological and functional alterations in the brain and is associated with learning and memory deficits (24). Our results illustrated that naringin significantly inhibited the oxidative stresses (decreased SOD and increased MDA content) to improve cognition in diabetic rats. Additionally, in human diabetes, inflammatory cytokines could cause serious neuronal damages in the hippocampus, be involved in the occurrence of neurodegenerative diseases, and be negatively correlated with cognitive deficits (25-26). In the current research, the activities of major inflammatory cytokines including TNF-α, IL-1β, and IL-6 were all augmented in the diabetic rat hippocampus, and naringin treatment significantly inhibited the proinflammatory response, to improve the cognitive decline in DACD.

PPARγ agonists are used for their therapeutic potential in diabetes mellitus. Pioglitazone is a highly selective PPARγ agonist that improves insulin-mediated glucose, and is widely used for patients with type 2 diabetes mellitus (T2DM) (27). It can increase insulin sensitivity, reduce blood glucose, and lower blood pressure in insulin-resistant rhesus monkey (28), and has a protective effect against oxidative stress in liver and kidney of diabetic rabbits (29). Recent findings in experimental models and in the clinical settings suggest that PPARγ agonists improve hippocampus-dependent cognitive deficits in brain disorders (27, 30). PPARγ agonists can be used for treating the cognitive dysfunction by reducing brain β-amyloid through PPARγ activation (31). Naringin has a partial agonistic effect on PPARγ, and increases PPARγ to ameliorate insulin resistance, dyslipidaemia, β-cell dysfunction, kidney damage, and hepatic steatosis in type 2 diabetic rats (22). In this study, we also speculate that the downregulation of PPARγ may be a leading cause of cognitive deficits in streptozotocin-induced diabetic rats and the pretreatment with naringin significantly increases PPARγ expression. We assessed the effects of naringin on DACD using a STZ-injected rat model, and the results showed that naringin significantly increased PPARγ expression. In all, naringin exerts an antidiabetic effect, possess antioxidant, anti-inflammatory, and a partial agonistic effects on PPARγ.

### Conclusion

The results of the current study showed that learning and memory functions are decreased by diabetes, and naringin may be a suitable medicine to
improve learning and memory performances in DACD. Its neuroprotective, antioxidant, and anti-inflammatory effects could ameliorate DACD via modulation of PPARγ.

Acknowledgment

This study was supported in part by the Scientific Research Fund of Hunan Provincial Education Department (60010511), the Science and Technology Foundation of Changsha City (K1403011-31), and the Innovative Projects for College Students in Hunan Province (1021-0001-017-062).

References

1. Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 2000; 23:542-549.
2. Biessels GJ, Kappelle AC, Bravenboer B, Erkelens DW, Gispen WH. Cerebral function in diabetes mellitus. Diabetologia 1994; 37:643-650.
3. Mijnhout GS, Schelten S, Diamant M, Biessels GJ, Wessels AM, Simsek S, Snoek FJ, Heine RJ. Diabetic encephalopathy: A concept in need of a definition. Diabetologia 2006; 49:1447-1448.
4. Kold CL, Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocr Rev 2008; 29:494-511.
5. Li WA, Moore-Langston S, Chakraborty T, Raffols JA, Conti AC, Ding Y. Hyperglycemia in stroke and possible treatments. Neurol Res 2013; 35:479-491.
6. Harada S, Fujita-Hamabe W, Tokuyama S. Ameliorating effect of hypothalamic brain-derived neurotrophic factor against impaired glucose metabolism after cerebral ischemic stress in mice. J Pharmacol Sci 2012; 118:109-116.
7. Morabito MV, Berman DE, Schneider RT, Zhang Y, Leibel RL, Small SA. Hyperleucocinemia causes hippocampal retromer deficiency linking diabetes to Alzheimer's disease. Neurobiol Dis 2014; 65:188-192.
8. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444:860-867.
9. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Investig 2013; 114:1752-1761.
10. Feng X, Gao X, Jia Y, Zhang H, Pan Q, Yao Z, Yang N, Liu J, Xu Y, Wang G, Yang X. PPAR-α agonist fenofibrate decreased serum irisin levels in type 2 diabetes patients with hypertriglyceridemia. PPAR Res 2015; 501:924131.
11. Saito T, Hasegawa-Moriyama M, Kurimoto T, Yamada T, Inada E, Kanmura Y. Resolution of inflammation by resolin D1 is essential for peroxisome proliferator-activated receptor-γ-mediated analgesia during postincisional pain development in type 2 diabetes. J Am Soc Anesthesiol 2015; 123:1420-1434.
12. Lee TT, Kao YH, Chen YC, Pan NH, Lin YK, Chen YJ, Cardiac peroxisome proliferator-activated receptor expression in hypertension co-existing with diabetes. Clin Sci 2011; 121:305-312.
13. Pereira RM, Andrades NE, Paulino N, Sawaya AC, Eberlin MN, Marucci MC, Favero GM, Novak EM, Bydłowski SP. Synthesis and characterization of a metal complex containing Naringin and Cu, and its antioxidant, antimicrobial, anti-inflammatory and tumor cell cytotoxicity. Molecules 2007; 12:1352-1366.
14. Cui L, Zhang ZH, Sun E, Jia XB. Effect of β-cyclodextrin complexation on solubility and enzymatic conversion of naringin. Int J Mol Sci 2012; 13:14251-14261.
15. Wang DM, Yang YJ, Zhang L, Zhang X, Guan FF, Zhang LF. Naringin Enhances CaMKII Activity and Improves Long-Term Memory in a Mouse Model of Alzheimer's Disease. Int J Mol Sci 2013; 14:5576-86.
16. Prakash A, Shur B, Kumar A. Naringin protects memory impairment and mitochondrial oxidative damage against aluminum-induced neurotoxicity in rats. Int J Neurosci 2013; 123:636-645.
17. Wang D, Gao K, Li X, Shen X, Zhang X, Ma C, Qin C, Zhang L. Long-term Naringin consumption reverses a glucose uptake defect and improves cognitive deficits in a mouse model of Alzheimer's disease. Pharmacol Biochem Behav 2012; 102:13-20.
18. Golechha M, Chaudhry U, Bhatia J, Saluja D, Arya DS. Naringin protects against kainic acid-induced status epilepticus in rats: evidence for an antioxidant, anti-inflammatory and neuroprotective intervention. Biol Pharm Bull 2011; 34:360-365.
19. Zhang M, Lv XY, Li J, Xu ZG, Chen L. The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp Diabetes Res 2008; 2008:704045.
20. Li R, Zang A, Zhang L, Zhang H, Zhao L, Qi Z, Wang H. Chrysin ameliorates diabetes-associated cognitive deficits in Wistar rats. Neurol Sci 2014; 35:1527-1532.
21. Hakeem P, Sani HA, Noor MM. Effects of gynura procumbens extract and glibenclamide on sperm quality and specific activity of testicular lactate dehydrogenase in streptozotocin-induced diabetic rats. J Complement Integr Med 2015; 16:10-14.
22. Sharma AK, Bharti S, Ojha S, Bhatia J, Kumar N, Ray R, Kumari S, Arya DS. Up-regulation of PPARγ, heat shock protein-27 and -72 by Naringin attenuates insulin resistance, β-cell dysfunction, hepatic steatosis and kidney damage in a rat model of type 2 diabetes. Br J Nutr 2011; 106:1713-1723.
23. Kandhare AD, Raygude KS, Ghosh P, Gule AE, Bodhankar SL. Neuroprotective effect of naringin by modulation of endogenous biomarkers in streptozotocin induced painful diabetic neuropathy. Fitoterapia 2012; 83:650-659.
24. Fukui K, Onodera K, Shinkai T, Suzuki S, Urano S. Impairment of learning and memory in rats caused by oxidative stress and aging, and changes in antioxidative defense systems. Ann N Y A Sci 2001; 928:168-175.
25. Liu YW, Zhu X, Li W, Lu Q, Wang JY, Wei YQ, Yin XX. Ginsenoside reattenuates diabetes-associated cognitive deficits in rats. Pharm Biochem Behav 2012; 101:93-98.
26. Deng W, Lu H, Teng J. Carvacrol attenuates diabetes-associated cognitive deficits in rats. J Mol Neurosci 2013; 51:813-819.
27. Sood V, Colleran K, Burge MR. Thiazolidinediones: a comparative review of approved uses. Diabetes Technol Ther 2000; 2:429-440.
28. Kemnitz JW, Elson DF, Roecker EB, Baum ST, Bergman RN, Meglasson MD. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure in obese, insulin-resistant Rhesus monkeys. Diabetes 1994; 43:204-211.
29. Gumieniczek A. Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits. Life Sci 2003; 74:553-562.
30. Jahrling JB, Hernandez CM, Denner L, Dineley KT. PPARγ recruitment to active ERK during memory consolidation is required for Alzheimer's disease-related cognitive enhancement. J Neurosci 2014; 34:4054-63.
31. Liu LP, Yan TH, Jiang LY, Hu W, Hu M, Wang C, Zhang Q, Long Y, Wang JQ, Li YQ, Hu M, Hong H. Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain β-amyloid through PPARγ activation. Acta Pharmacol Sin 2013; 34:455-463.